Evolus (NASDAQ:EOLS) Announces Earnings Results

Evolus (NASDAQ:EOLS) announced its quarterly earnings data on Monday. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02), FiscalAI reports. The business had revenue of $73.14 million for the quarter, compared to analysts’ expectations of $72.52 million. During the same quarter in the previous year, the firm posted ($0.30) earnings per share.

Here are the key takeaways from Evolus’ conference call:

• Positive adjusted EBITDA for the second consecutive quarter (adjusted EBITDA of $0.6M) and an adjusted gross margin around 68%, reflecting the 2025 cost-structure changes and improving operating leverage.
• Company revenue was $73.1M in Q1 (+7% YoY) with Jeuveau generating $66.4M and U.S. market share held at 14%, supported by unit growth domestically and internationally.
• Management reiterated full-year 2026 guidance of $327M–$337M in net revenue, reiterated expectations for double-digit revenue growth and full-year adjusted EBITDA profitability, and kept its long-term outlook through 2028 unchanged.
• Near-term growth catalysts include the mid-May launch of Estyme in Europe, an expected FDA decision for Sculpt in Q4 2026, expanding portfolio bundling programs, and increased use of AI-driven commercial tools and Evolus Rewards (~1.5M members) to drive adoption.
• A newly announced 15% tariff on certain pharmaceuticals from South Korea (effective Sept 29, 2026) could increase costs for Jeuveau; the company is pursuing mitigation options and short-term inventory strategies but notes uncertainty remains.

Evolus Stock Performance

EOLS opened at $5.58 on Tuesday. The firm’s fifty day moving average is $4.68 and its two-hundred day moving average is $5.63. The firm has a market cap of $363.03 million, a PE ratio of -6.89 and a beta of 1.28. Evolus has a twelve month low of $3.86 and a twelve month high of $12.24.

Analyst Ratings Changes

A number of equities analysts have issued reports on the stock. Mizuho set a $15.00 price objective on shares of Evolus in a research note on Wednesday, February 4th. Wall Street Zen cut shares of Evolus from a “buy” rating to a “hold” rating in a research note on Sunday, March 15th. Weiss Ratings cut shares of Evolus from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, April 24th. BTIG Research reaffirmed a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research note on Wednesday, March 4th. Finally, HC Wainwright reduced their price objective on shares of Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a research note on Tuesday, February 3rd. Four investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Evolus currently has a consensus rating of “Moderate Buy” and a consensus target price of $16.00.

Insider Buying and Selling at Evolus

In other Evolus news, insider Rui Avelar sold 29,996 shares of the stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $4.89, for a total value of $146,680.44. Following the sale, the insider directly owned 430,542 shares in the company, valued at approximately $2,105,350.38. This trade represents a 6.51% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider David Moatazedi sold 13,669 shares of the stock in a transaction on Friday, March 20th. The stock was sold at an average price of $4.75, for a total transaction of $64,927.75. Following the completion of the sale, the insider owned 604,700 shares in the company, valued at approximately $2,872,325. This trade represents a 2.21% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 163,504 shares of company stock worth $797,184. Company insiders own 5.90% of the company’s stock.

Institutional Investors Weigh In On Evolus

Several hedge funds have recently bought and sold shares of EOLS. Meeder Asset Management Inc. acquired a new stake in shares of Evolus during the fourth quarter worth $34,000. Wexford Capital LP acquired a new stake in shares of Evolus during the third quarter worth $37,000. Tower Research Capital LLC TRC raised its holdings in shares of Evolus by 340.2% during the second quarter. Tower Research Capital LLC TRC now owns 7,364 shares of the company’s stock worth $68,000 after acquiring an additional 5,691 shares during the period. Aquatic Capital Management LLC acquired a new stake in shares of Evolus during the third quarter worth $48,000. Finally, State of Wyoming acquired a new stake in shares of Evolus during the fourth quarter worth $63,000. 90.69% of the stock is currently owned by institutional investors and hedge funds.

Evolus News Summary

Here are the key news stories impacting Evolus this week:

• Positive Sentiment: Q1 revenue beat estimates ($73.14M vs. $72.52M consensus) and the quarterly loss narrowed versus last year, which supports revenue momentum. Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates
• Positive Sentiment: Company delivered its second consecutive quarter of positive adjusted EBITDA and management emphasized progress toward profitable growth — a key bullish signal for investors focused on path to sustained profitability. Evolus Reports First Quarter 2026 Financial Results
• Positive Sentiment: Evolus reaffirmed FY2026 revenue guidance of $327M–$337M (roughly in line with street expectations), reducing uncertainty around the full‑year outlook. Evolus Reports First Quarter 2026 Financial Results
• Neutral Sentiment: Management struck an upbeat tone on the earnings call and provided color on execution and demand trends; call transcript and highlights are available for investors who want details. Evolus Earnings Call Highlights Profitable Growth Path
• Neutral Sentiment: Company provided slide deck and conference call materials for deeper due diligence; useful but unlikely to move the stock by itself. Evolus Earnings / Conference Call Materials
• Negative Sentiment: GAAP EPS missed consensus by $0.02 (reported ($0.16) vs. ($0.14) expected) — investors sensitive to profitability metrics may view the miss negatively. Evolus Q1 2026 Press Release / Financials
• Negative Sentiment: Stock has shown longer‑term weakness (50‑day MA below 200‑day MA) and the company remains unprofitable on GAAP basis — structural risks that can cap upside until consistent positive earnings are delivered.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.